期刊文献+

整合埃博拉病毒囊膜蛋白的伪病毒的构建

Construction of Ebola virus glycoprotein-pseudotyped lentivirus
下载PDF
导出
摘要 埃博拉病毒(EBOV)是一种能够引起人类和灵长类动物的烈性出血热的病原体,致死率高达90%。对该病毒活病毒的操作仅能够在生物安全4级实验室进行,高级别的生物安全要求限制了病毒的研究。为建立一个能够表达EBOV囊膜蛋白(GP)的伪病毒,本研究利用表达GP基因的重组质粒,与囊膜蛋白缺失、表达绿色荧光蛋白(GFP)的人免疫缺陷病病毒1型(HIV-1)基因组的重组质粒共转染人胚胎肾细胞(293T),以包装整合含有囊膜蛋白的伪型EBOV。结果表明,EBOV GP蛋白能够正确组装至HIV-1病毒表面;利用组装的伪型病毒粒子感染293T、人宫颈癌细胞(Hela)、人骨肉瘤细胞(Ghost)和非洲绿猴肾细胞(Vero)几种细胞系,结果显示在不同细胞系中均可检测到GFP蛋白的表达,表明组装的伪型病毒可以模拟野生型病毒感染相关细胞。本研究构建的伪型EBOV作为活病毒的替代工具,为研究EBOV的感染机制及中和抗体的筛选提供了一个良好的平台。 Ebola virus, the pathogen of Ebola haemorrhagic fever, causes human and primates severe disease and high case-fatality rates (up to 90%). As a highly contagious pathogen, the operation of live viruses has to be conducted in biosafety- level 4 facilities. In order to develop a surrogate for live virus, Ebola virus glycoprotein (Ebola-GP) expressing recombinant plasmid was co-transfected with human immunodeficiency syndrome virus (HIV-1) based retroviral vector into human embryonic kidney (HEK) 293T cells for the construction of the Ebola-GP pseudotyped lentivirus. Results showed that the Ebola GP successfully packaged with H1V-1 viral genome. In addition, the expression of reporter gene (GPF) could be detected in Ghost, Vero, 293T and Hela cells when the pseudotyped viruses were used to infect these cells lines, suggesting that the GP-pseudotyped lentiviruses were able to mimic the live viruses to infect target cells. This study provided an practically platform for further research on the mechanism of virus infection and Ebola virus neutralizing antibody screening.
出处 《中国预防兽医学报》 CAS CSCD 北大核心 2015年第12期926-929,共4页 Chinese Journal of Preventive Veterinary Medicine
基金 兽医生物技术国家重点实验室自主课题(SKLVBP2015012)
关键词 埃博拉病毒 伪病毒 囊膜蛋白 Ebola virus pseudotyped virus glycoprotein
  • 相关文献

参考文献13

  • 1付辉,刘小利.西非埃博拉疫情蔓延原因浅析[J].中华灾害救援医学,2014,2(9):539-540. 被引量:8
  • 2Dolnik O, Kolesnikova L, Becker S. Filoviruses: Interactions with the host cell [J]. CMLS, 2008, 65(5): 756-776.
  • 3Rouven J, Wool L, Paul B, et al. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines [J]. J Virol, 1998, 72(4): 3155-3160.
  • 4史子学,赵晓明,丁晓东,朱冬冬,曹传闺,张国平.埃博拉病毒感染猪的研究进展[J].猪业科学,2014,31(2):86-87. 被引量:7
  • 5Towner J S, Sealy T K, Khristova M L, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda [J]. PLos Pathog, 2008, 4(11): 3155-3160.
  • 6Volchkov V E, Becker S, Volchkova V A, et al. GP mRNA of ebola virus is edited by the ebola virus polymerase [J]. Virology, 1995, 214(2): 421-430.
  • 7Sanchez A, Trappier S G, Mahy B W, et al. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing [J]. Proc Natl Acad Sci, 1996, 93(8): 3602-3607.
  • 8Volchkova V A, Feldmann H, Klenk H D, et al. The nonstructural small glycoprotein sGP of Ebola virus is secreted as an antiparallel-orientated homodimer [J]. Virology, 1998, 250(2): 408-414.
  • 9Hood C L, Abraham J, Boyington J C, et al. Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity [J]. J Virol, 2010, 84(6): 2972-2982.
  • 10Wang Bin, Liu Pei-xin, et al. Package of NDV-pseudotyped HIV-Luc virus and its application in the neutralization assay for NDV infection [J]. PLoS One, 2014, 9(6): e99905.

二级参考文献36

  • 1刘华雷,Rong Li-Jun,周斌,魏建超,郑其升,陈溥言.表达H5N1亚型禽流感病毒HA蛋白的重组鼠白血病病毒的特性[J].生物工程学报,2005,21(1):47-51. 被引量:9
  • 2Wool-Lewis R J, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines [J]. J Virol, 1998, 72: 3155-3160.
  • 3Garten R J, Davis C T, Russell C A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans [J]. Science, 2009, 325: 197-201.
  • 4Rota P A, Oberste M S, Monroe S S, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome[J]. Science, 2003, 300(5624): 1394-1399.
  • 5Orellana C. Laboratory-acquired SARS raises worries on biosafety[J]. Lancet Infect Dis, 2004, 4:64.
  • 6Wu H S, Chiu S C, Tseng T C, et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan[J]. Emerg Infect Dis, 2004,10:304-310.
  • 7Xiao X, Chakraborti S, Dimitrov A S, et al. The SARS-CoV S glycoprotein: expression and functional characterization[J]. Biochem Biophys Res Commun, 2003,312 (4) :1159-1164.
  • 8Jiang S, He Y, Liu S. SARS vaccine development[J]. Emerg Infect Dis, 2005,11 (7) : 1016-1020.
  • 9Yang Z Y, Kong W P, Huang Y, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice[J]. Nature, 2004,428 (6982) : 561-564.
  • 10Chen Z, Zhang L, Qin C, et al. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region[J]. J Virol, 2005,79 (5) : 2678- 2688.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部